The conflict centers on Aurora’s at-the-market (ATM) program, which Curaleaf seeks to halt through a regulatory filing. Miguel Martin, Aurora’s Executive Chairman and CEO, rejected the premise that the program reflects the company’s current valuation. He emphasized that the facility was established in February 2026—months before the hostile bid emerged—to fund international expansion and strategic acquisitions, such as recent investments in the UK market.
Aurora Cannabis rebuffs Curaleaf's bid to halt market program
Aurora Cannabis has dismissed a recent legal maneuver by Curaleaf to suspend its at-the-market equity program, labeling the move a diversionary tactic. As the hostile takeover battle intensifies, Aurora’s leadership insists the program is a long-standing growth tool rather than a reactionary measure to Curaleaf’s acquisition attempt.
Aurora’s board remains firm in its opposition, urging shareholders to reject the takeover. The company contrasts its own debt-free status against the more than $1 billion in debt held by Curaleaf, which includes $500 million in notes carrying an 11.5% interest rate. According to Aurora, this financial burden poses significant risks to potential investors. Following a unanimous recommendation from its Special Committee, the company has advised shareholders to take no action and withdraw any shares already tendered to the hostile offer, citing unresolved regulatory deficiencies in the Curaleaf bid currently under review by the Alberta Securities Commission.
Comments (0)
No comments yet. Be the first!